MS review: The division of MS in "types" was made up just to approve interferons
Posted: Mon Mar 04, 2019 3:15 am
Multiple sclerosis – a review
https://onlinelibrary.wiley.com/doi/ful ... /ene.13819
There has been a reduction in the proportion of people with PPMS. This is probably related to the fact that there are no licensed treatments for PPMS; patients may be labelled as having relapsing MS in order to receive treatment, raising ethical questions about the division of MS into distinct subtypes. This artificial division of MS into different diseases was driven by the pharmaceutical industry to get interferon beta licensed under the Orphan Drug Act in the USA.
Here there is a longer explanation:
https://multiple-sclerosis-research.org ... -kool-aid/
The construct that MS has distinct phases, an early inflammatory and a delayed degenerative phase, is artificial and comes from the Pharma industry’s need to get interferon-beta licensed under the orphan drug act, i.e. MS had to have a prevalence of fewer than 200,000 affected people for the orphan drug act to apply. The only way to get the numbers down to less than 200,000 was to salami-slice up MS into three diseases, i.e. RRMS, SPMS and PPMS.
https://onlinelibrary.wiley.com/doi/ful ... /ene.13819
There has been a reduction in the proportion of people with PPMS. This is probably related to the fact that there are no licensed treatments for PPMS; patients may be labelled as having relapsing MS in order to receive treatment, raising ethical questions about the division of MS into distinct subtypes. This artificial division of MS into different diseases was driven by the pharmaceutical industry to get interferon beta licensed under the Orphan Drug Act in the USA.
Here there is a longer explanation:
https://multiple-sclerosis-research.org ... -kool-aid/
The construct that MS has distinct phases, an early inflammatory and a delayed degenerative phase, is artificial and comes from the Pharma industry’s need to get interferon-beta licensed under the orphan drug act, i.e. MS had to have a prevalence of fewer than 200,000 affected people for the orphan drug act to apply. The only way to get the numbers down to less than 200,000 was to salami-slice up MS into three diseases, i.e. RRMS, SPMS and PPMS.